Paradigm Capital Management Inc. NY Takes $24.54 Million Position in Natera, Inc. $NTRA

Key Points

• Paradigm Capital Management acquired 90,400 Natera shares worth approximately $24.54 million in the second quarter, while institutional investors collectively own 99.90% of the company.
• Natera reported quarterly revenue of $752.75 million, up 37.7% year over year and above expectations, while its adjusted loss of $0.47 per share narrowly beat analyst estimates.
• Natera shares opened at $327.72, near their 12-month high, and analysts maintain a “Moderate Buy” consensus with an average price target of $319.38; insiders have sold about $40.7 million in stock over the past 90 days.

Paradigm Capital Management Inc. NY bought a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 90,400 shares of the medical research company's stock, valued at approximately $24,539,000. Natera comprises about 0.7% of Paradigm Capital Management Inc. NY's investment portfolio, making the stock its 29th biggest holding. Paradigm Capital Management Inc. NY owned approximately 0.06% of Natera as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in NTRA. BlackRock Inc. purchased a new stake in Natera in the 2nd quarter valued at about $2,962,770,000. Coatue Management LLC increased its stake in shares of Natera by 1,446.1% during the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company's stock valued at $603,270,000 after acquiring an additional 2,463,008 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Natera by 94.7% during the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company's stock worth $1,140,026,000 after acquiring an additional 2,420,263 shares during the period. Norges Bank purchased a new position in shares of Natera during the 4th quarter worth about $372,398,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Natera by 10.5% in the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company's stock worth $2,944,800,000 after acquiring an additional 1,225,420 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Natera

In other news, Director Herm Rosenman sold 16,530 shares of the company's stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total value of $4,132,500.00. Following the completion of the sale, the director owned 4,250 shares of the company's stock, valued at $1,062,500. This represents a 79.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 3,410 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $265.58, for a total value of $905,627.80. Following the completion of the sale, the insider owned 129,019 shares of the company's stock, valued at approximately $34,264,866.02. This trade represents a 2.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 177,955 shares of company stock valued at $40,704,193 over the last 90 days. Corporate insiders own 5.05% of the company's stock.

Natera Trading Down 1.3%

NASDAQ:NTRA opened at $327.72 on Tuesday. The firm has a market capitalization of $47.24 billion, a price-to-earnings ratio of -240.97 and a beta of 1.51. The firm's fifty day simple moving average is $276.45 and its 200 day simple moving average is $230.09. Natera, Inc. has a twelve month low of $157.43 and a twelve month high of $333.56.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm had revenue of $752.75 million during the quarter, compared to analysts' expectations of $661.24 million. During the same period in the prior year, the company earned ($0.74) EPS. The firm's revenue was up 37.7% on a year-over-year basis. On average, analysts predict that Natera, Inc. will post -1.02 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on NTRA shares. Wall Street Zen downgraded shares of Natera from a "buy" rating to a "hold" rating in a report on Saturday, May 9th. Barclays reaffirmed an "overweight" rating and set a $340.00 price target on shares of Natera in a research note on Friday, August 7th. UBS Group set a $260.00 price objective on shares of Natera in a research note on Wednesday, June 24th. Stephens upped their price objective on Natera from $305.00 to $350.00 and gave the stock an "overweight" rating in a report on Wednesday, August 12th. Finally, Wolfe Research initiated coverage on Natera in a report on Tuesday, June 2nd. They set an "outperform" rating and a $260.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Natera has an average rating of "Moderate Buy" and a consensus price target of $319.38.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source